22nd Century Group (XXII) is a cannabis biotech company trading on the NASDAQ. The stock is currently priced at $0.0971 with a market capitalization of $69.3K and trailing twelve-month revenue of $14.5M. View SEC filings ↗
Market Cap
$69.3K
Volume
30.0M
Prev Close
$0.10
52W High
$540.00
52W Low
$0.0865
P/S Ratio
0.00
Shares Out
714.0K
Revenue
$14.5M
Gross Margin
N/A
Cash
$6.1M
XXII Price Chart
Latest Quarterly Results
In Q2 2026, 22nd Century Group reported revenue of $2.9M, down 29.9% from Q2 2025. The net loss was $3.3M. The company ended the quarter with $6.1M in cash and $560.0K of debt.
| XXII | Q2 2026 | YoY |
|---|---|---|
| Revenue | $2.9M | -29.9% |
| Gross margin | — | — |
| Net income | -$3.3M | — |
| Operating cash flow | -$4.0M | — |
| Cash & equivalents | $6.1M | +96.5% |
| Total debt | $560.0K | -82.6% |
Source: SEC filings, in USD; quarters are calendar quarters of the period end. Latest filing: 10-Q, filed Aug 14, 2026 ↗. Next report expected around Nov 16, 2026 (estimate).
Trading Data
Valuation Metrics
Financial Highlights
View Full FinancialsQuarterly Revenue
Reported quarterly revenue (SEC filings)
TTM: $14.5M
XXII Key Takeaways
- 22nd Century Group (XXII) trades at $0.0971 with a market cap of $69.3K, ranking #70 among 71 cannabis stocks.
- Trailing twelve-month revenue is $14.5M, declining -27.44% year-over-year.
- Balance sheet shows $6.1M cash against $560.0K debt — net cash positive.
- Price-to-Sales ratio of 0.00x — below sector median, potentially undervalued.
- Ranked #4 by market cap in the Biotech sector. Trades on the NASDAQ exchange.
XXII Stock Analysis
22nd Century Group (XXII) is a cannabis biotech company listed on the NASDAQ exchange, headquartered in the United States. With a current share price of $0.0971 and a market capitalization of $69.3K, XXII ranks #70 out of 71 publicly traded cannabis stocks tracked on Cannabismarketcap.
From a fundamental perspective, 22nd Century Group reports trailing twelve-month revenue of $14.5M, representing a decline of -27.44% year-over-year. At a price-to-sales multiple of 0.00x, the stock appears attractively valued relative to its revenue base.
The company's balance sheet shows $6.1M in cash and equivalents against $560.0K in total debt, resulting in a healthy net cash position of $5.5M. At the current burn rate, estimated cash runway is approximately 9 months. Investors looking for a deeper dive can explore XXII's full financial statements including quarterly breakdowns and balance sheet history.
XXII currently trades within a 52-week range of $0.0865 to $540.00. Average daily trading volume stands at 30.0M shares. The company employs approximately 56 people.
Corporate Information
Share Structure
XXII Price History
Investment Snapshot
Programmatic analysis based on available financial data. Not investment advice.
Ranked #70 of 71 by market cap ($69.3K). Sector median: $32.9M.
Net cash: $5.5M ($6.1M cash, $560.0K debt).
Revenue growth at -27.4% YoY. Sector median: +1.6%.
P/S ratio of 0.00x vs sector median of 0.71x. Potentially undervalued.
Cannabis Industry Context
Cannabis Industry Overview
The cannabis biotech sector sits at the intersection of pharmaceutical development and plant-based therapeutics, encompassing companies pursuing FDA-approved cannabinoid medicines, novel drug delivery systems, and clinical-stage research into the endocannabinoid system. Unlike plant-touching operators, cannabis biotechs operate within the established FDA regulatory pathway, conducting preclinical studies and multi-phase clinical trials to demonstrate safety and efficacy for specific therapeutic indications. Epidiolex, a purified CBD formulation approved for rare forms of epilepsy, demonstrated that FDA approval of cannabis-derived pharmaceuticals is achievable and can unlock institutional healthcare investment. The broader pipeline spans indications including chronic pain, PTSD, anxiety, inflammation, and neurological disorders. Biotech investors evaluate these companies using traditional pharmaceutical metrics: pipeline depth, clinical trial stage, probability of regulatory approval, intellectual property protection, and total addressable market for each indication. The sector carries binary risk profiles typical of early-stage drug development but offers significant upside if clinical programs achieve regulatory milestones.
22nd Century Group in the Cannabis Biotech Landscape
22nd Century Group (XXII) currently ranks #4 out of 4 publicly traded cannabis biotech companies by market capitalization, with a market cap of $69.3K. The company reports trailing-twelve-month revenue of $14.5M, placing it below the sector median of $34.5M. The cannabis biotech sector comprises 4 tracked companies, reflecting the focused competitive landscape within this segment of the cannabis industry.
The top companies in the cannabis biotech sector by market capitalization are Jazz Pharmaceuticals (JAZZ) at $13.30B, InnocanPharma (INNPF) at $93.1M, and BioHarvest Sciences (BHST) at $39.2M. 22nd Century Group competes within this group for market share, investor attention, and operational scale as the sector continues to mature.
Key Metrics at a Glance
Regulatory & Risk Considerations
All cannabis investors should be aware that federal legalization status in the United States remains uncertain. While cannabis is legal for medical use in the majority of US states and for adult use in a growing number of jurisdictions, it remains classified as a Schedule I controlled substance at the federal level. This creates material legal, financial, and operational risks across the industry. Cannabis biotech companies like 22nd Century Group are subject to the rigorous and time-consuming FDA regulatory pathway, which can span 10-15 years and hundreds of millions of dollars from discovery through Phase III clinical trials and New Drug Application (NDA) review. Binary outcomes at each clinical stage create significant volatility, and the majority of drug candidates do not reach commercial approval.
Unique to cannabis biotech is the interaction between the FDA pharmaceutical pathway and the evolving state and federal cannabis regulatory environment. Companies must navigate DEA scheduling requirements for research materials, secure appropriate supply agreements for clinical-grade cannabinoids, and manage intellectual property in a space where natural compounds face patentability challenges. If cannabis is rescheduled or descheduled, the competitive landscape could shift as consumer access to cannabinoid products expands through non-pharmaceutical channels.
Compare XXII With Peers
Related Biotech Stocks
Frequently Asked Questions
What is 22nd Century Group's (XXII) stock price today?▼
22nd Century Group (XXII) stock is currently trading at $0.0971 per share on the NASDAQ exchange. This represents a daily decline of -7.35% ($0.0077) from the previous closing price of $0.10. Over the past 52 weeks, XXII has traded between a low of $0.0865 and a high of $540.00, placing the current price at approximately -100% from its annual high. The stock has a market capitalization of $69.3K, making it a notable cannabis companies tracked by Cannabismarketcap. 22nd Century Group operates in the Biotech sector, classified under "CIGARETTES", serving the broader cannabis industry.
What is 22nd Century Group's market capitalization?▼
22nd Century Group (XXII) has a current market capitalization of $69.3K, calculated by multiplying its 714.0K shares outstanding by the current stock price of $0.0971. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places 22nd Century Group among the small-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at -$5.4M, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.
What is 22nd Century Group's annual revenue?▼
22nd Century Group (XXII) reports trailing twelve month (TTM) revenue of $14.5M, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed -27.44% year-over-year, reflecting a contraction in top-line performance relative to the prior period. The current price-to-sales ratio is 0.00x, which means investors are paying $0.00 for every $1 of annual revenue — a relatively low valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.
How many employees does 22nd Century Group have?▼
22nd Century Group currently employs approximately 56 people across its operations. As a cannabis biotech company headquartered in the United States, its workforce supports activities spanning cigarettes and related business functions. Based on trailing twelve month revenue of $14.5M, this equates to approximately $259.2K in revenue per employee, which is a useful efficiency metric for comparing operational productivity across cannabis companies. Employee count is an important indicator of a company's operational scale and its capacity for growth in an industry that remains highly labor-intensive due to regulatory requirements.
What exchange is XXII listed on?▼
22nd Century Group trades under the ticker symbol XXII on the NASDAQ exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts. The company has been publicly listed since 2011-01-26, giving it a track record in the public markets that investors can analyze for long-term trends. The stock sees average daily trading volume of approximately 30.0M shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.
What is XXII's 52-week trading range?▼
22nd Century Group (XXII) has traded between a 52-week low of $0.0865 and a 52-week high of $540.00, with the current price of $0.0971 sitting approximately -100% from the annual high. This range represents a spread of $539.91 (624177% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.
What is 22nd Century Group's cash position and debt level?▼
22nd Century Group (XXII) holds $6.1M in cash and equivalents on its balance sheet, set against $560.0K in total debt. This gives the company a net cash position of $5.5M. At the current rate of cash usage, the company has an estimated cash runway of approximately 9 months before needing additional financing, which could come from operations, debt, or equity issuance. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.
How many shares outstanding does 22nd Century Group have?▼
22nd Century Group (XXII) currently has 714.0K shares outstanding, which when multiplied by the current stock price of $0.0971 gives the company its market capitalization of $69.3K. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.
Embed XXII Widget
Add the XXII price widget to your website or blog:
<iframe src="https://cannabismarketcap.io/embed/xxii" width="320" height="180" frameborder="0" style="border-radius:8px;border:1px solid #415a77"></iframe>Data updates every 2 minutes. Free for non-commercial use.
Disclaimer
The information on this page is provided for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Cannabismarketcap is not a registered broker-dealer or investment advisor. All data, including stock prices, market capitalizations, financial metrics, and analysis for 22nd Century Group (XXII), is provided “as is” without warranty of any kind. Past performance does not guarantee future results. Cannabis stocks are highly volatile and carry significant risk, including the potential for total loss of investment. Marijuana remains illegal under federal law in the United States. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions. Data may be delayed or inaccurate. See our terms of service and privacy policy for more information.